Treatment of kaposi's sarcoma with vinblastine

Fourteen patients with Kaposi's sarcoma (KS) were treated systemically with vinblastine sulfate in a low‐dose regimen and compared with 23 patients reported in the medical literature. The therapeutic results in our series were excellent in terms of regression of cutaneous lesions. Vinblastine a...

Full description

Saved in:
Bibliographic Details
Published inCancer Vol. 45; no. 3; pp. 427 - 431
Main Authors Klein, Edmund, Schwartz, Robert Allen, Laor, Yona, Milgrom, Halina, Burgess, Gordon H., Holtermann, Ole A.
Format Journal Article
LanguageEnglish
Published New York Wiley Subscription Services, Inc., A Wiley Company 01.02.1980
Subjects
Adult
Aged
Female
Humans
Leukopenia - chemically induced
Male
Middle Aged
Remission, Spontaneous
Sarcoma, Kaposi - drug therapy
Skin Neoplasms - drug therapy
Time Factors
Vinblastine - administration & dosage
Vinblastine - adverse effects
Vinblastine - therapeutic use
Online AccessGet full text

Cover

More Information
Summary:Fourteen patients with Kaposi's sarcoma (KS) were treated systemically with vinblastine sulfate in a low‐dose regimen and compared with 23 patients reported in the medical literature. The therapeutic results in our series were excellent in terms of regression of cutaneous lesions. Vinblastine appears to be a drug that is well suited for the management of KS in an outpatient setting. Intravenous therapy may be supplemented with intralesional or intraarterial vinblastine.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19800201)45:3<427::AID-CNCR2820450304>3.0.CO;2-1